Is FGF23 effective on insulin resistance in individuals with metabolic syndrome?
-
Dede Sit
,
Ender Tanrıverdi
Abstract
Purpose
Metabolic syndrome (MetS) is a polymetabolic syndrome has high morbidity and mortality rates. Insulin resistance (IR) plays a key role in the increasing frequency of this situation and has been cited as being an important etiologic factor in MetS. In this study, the relationship between IR and fibroblast growth factor-23 (FGF23), was investigated in a population with MetS.
Materials and methods
Forty patients with diagnosis of MetS and 40 healthy volunteers with an equal number of males and females were included in the study and classified as patient group and control group. Blood samples were obtained after 12-h fasting period to study FGF23 and other parameters. MetS, defined according to the International Diabetes Federation (IDF) guidelines, FGF23 was studied by Enzyme-Linked ImmunoSorbent Assay (ELISA) method and IR was calculated using the homeostatic model assessment-insulin resistance (HOMA-IR) formula.
Results
There was a statistically significant difference in HOMA-IR between the patient and control group as expected, while levels of FGF23 were similar. According to gender, levels of FGF23 was statistically significantly higher in male patients compared with controls (p = 0.037). A relationship was not detected between HOMA-IR and FGF23 in the correlation analysis.
Conclusion
Although there are many studies suggesting the correlation between FGF23 and IR in different populations, we did not find any statistically significant relationship between IR and FGF23 levels in MetS in this study.
Acknowledgment
The authors thank Muhammed Ali Sit from the University of Iowa Faculty of Engineering, for contributing to the linguistic review of the manuscript.
Author Statement
Research funding: Authors state no funding was involved.
Conflict of interest: The authors declare that there is no conflict of interests regarding the publication of this paper. None of the authors has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the results.
Informed consent: Informed written consents were assigned to all patients and control subjects.
Ethical approval: The research related to human use complied with all the relevant national regulations and institutional policies and was performed in accordance to the tenets of the Declaration of Helsinki and has been approved by the Ethical Committee of Non-Interventional Clinical Investigations in Bagcilar Training and Research Hospital.
References
[1] International Diabetes Federation. Medicine on the net. 2016; Available at: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf.Search in Google Scholar
[2] Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr. 2007;61:548–53.10.1038/sj.ejcn.1602554Search in Google Scholar PubMed
[3] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2486–97.10.1001/jama.285.19.2486Search in Google Scholar PubMed
[4] Alikaşifoğlu A, Gönç N, Özön ZA, Sen Y, Kandemir N. The relationship between serum adiponectin, tumor necrosis factor-alpha, leptin levels and insulin sensitivity in childhood and adolescent obesity: adiponectin is a marker of metabolic syndrome. J Clin Res Pediatr Endocrinol. 2009;1:233–9.10.4274/jcrpe.v1i5.233Search in Google Scholar PubMed PubMed Central
[5] Gateva A, Assyov Y, Tsakova A, Kamenov Z. Classical (adiponectin, leptin, resistin) and new (chemerin, vaspin, omentin) adipocytokines in patients with prediabetes. Horm Mol Biol Clin Investig. 2018. doi: 10.1515/hmbci-2017-0031.Search in Google Scholar PubMed
[6] Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003;149:331–5.10.1530/eje.0.1490331Search in Google Scholar PubMed
[7] Friedman J. The long road to leptin. J Clin Invest. 2016;126:4727–34.10.1172/JCI91578Search in Google Scholar PubMed PubMed Central
[8] Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82:737–47.10.1038/ki.2012.176Search in Google Scholar PubMed PubMed Central
[9] Garland JS, Holden RM, Ross R, Adams MA, Nolan RL, Hopman WM, et al. Insulin resistance is associated with fibroblast growth factor-23 in stage 3-5 chronic kidney disease patients. J Diabetes Complications. 2014;28:61–5.10.1016/j.jdiacomp.2013.09.004Search in Google Scholar PubMed
[10] Zaheer S, de Boer IH, Allison M, Brown JM, Psaty BM, Robinson-Cohen C, et al. Fibroblast growth factor 23, mineral metabolism, and adiposity in normal kidney function. J Clin Endocrinol Metab. 2017;102:1387–95.10.1210/jc.2016-3563Search in Google Scholar PubMed PubMed Central
[11] Grethen E, Hill KM, Jones R, Cacucci BM, Gupta CE, Acton A, et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab. 2012;97:1655–62.10.1210/jc.2011-2280Search in Google Scholar PubMed PubMed Central
[12] Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, Starzyk JB. FGF23 contributes to insulin sensitivity in obese adolescents – preliminary results. Clin Endocrinol (Oxf). 2012;77:537–40.10.1111/j.1365-2265.2011.04299.xSearch in Google Scholar PubMed
[13] Wojcik M, Janus D, Dolezal-Oltarzewska K, Drozdz K, Starzyk JB. The association of FGF23 levels in obese adolescents with insulin sensitivity. J Pediatr Endocrinol Metab. 2012;25:687–90.10.1515/jpem-2012-0064Search in Google Scholar PubMed
[14] Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205:385–90.10.1016/j.atherosclerosis.2009.01.001Search in Google Scholar PubMed
[15] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.10.1007/BF00280883Search in Google Scholar PubMed
[16] Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol. 2012;7:1155–62.10.2215/CJN.13281211Search in Google Scholar PubMed PubMed Central
[17] Tanaka S, Fujita S, Kizawa S, Morita H, Ishizaka N. Association between FGF23, α-Klotho, and cardiac abnormalities among patients with various chronic kidney disease stages. PLoS One. 2016;11:e0156860.10.1371/journal.pone.0156860Search in Google Scholar PubMed PubMed Central
[18] Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17:1305–15.10.1681/ASN.2005111185Search in Google Scholar PubMed
[19] Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195:125–31.10.1677/JOE-07-0267Search in Google Scholar PubMed
[20] Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluce H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int. 2014;85:142–50.10.1038/ki.2013.271Search in Google Scholar PubMed PubMed Central
[21] Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. J Am Med Assoc. 2011;305:2432–9.10.1001/jama.2011.826Search in Google Scholar PubMed PubMed Central
[22] Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393–408.10.1172/JCI46122Search in Google Scholar PubMed PubMed Central
[23] Mirza MA, Hansen T, Johansson L, Ahlström H, Larsson A, Lind L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant. 2009;24:3125–31.10.1093/ndt/gfp205Search in Google Scholar PubMed
[24] Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–92.10.1056/NEJMoa0706130Search in Google Scholar PubMed PubMed Central
[25] Kovesdy CP, Quarles LD. Fibroblast growth factor-23: what we know, what we don’t know, and what we need to know. Nephrol Dial Transplant. 2013;28:2228–36.10.1093/ndt/gft065Search in Google Scholar PubMed PubMed Central
[26] Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010;152:640–8.10.7326/0003-4819-152-10-201005180-00004Search in Google Scholar PubMed PubMed Central
[27] Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int. 2013;83:160–6.10.1038/ki.2012.327Search in Google Scholar PubMed
[28] Schendl C, Fahrleitner-Pammer A, Pietschmann P, Amrein K. FGF23 in acute and chronic illness. Dis Markers. 2015;2015:358086.10.1155/2015/358086Search in Google Scholar PubMed PubMed Central
[29] Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutiérrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One. 2015;10:e0122885.10.1371/journal.pone.0122885Search in Google Scholar PubMed PubMed Central
[30] Holecki M, Chudek J, Owczarek A, Olszanecka-Glinianowicz M, Bożentowicz-Wikarek M, Duława J, et al. Inflammation but not obesity or insulin resistance is associated with increased plasma fibroblast growth factor 23 concentration in the elderly. Clin Endocrinol (Oxf). 2015;82:900–9.10.1111/cen.12759Search in Google Scholar PubMed
[31] Fernández-Real JM, Puig J, Serrano M, Sabater M, Rubió A, Moreno-Navarrete JM, et al. Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations. PLoS One. 2013;8:e58961.10.1371/journal.pone.0058961Search in Google Scholar PubMed PubMed Central
©2018 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Original Articles
- Melatonin and cryptochrome 2 in metabolic syndrome patients with or without diabetes: a cross-sectional study
- Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome
- Is FGF23 effective on insulin resistance in individuals with metabolic syndrome?
- Review Article
- Circulating low density lipoprotein (LDL)
- Case Report
- Congenital complete heart block in pregnancy
Articles in the same Issue
- Original Articles
- Melatonin and cryptochrome 2 in metabolic syndrome patients with or without diabetes: a cross-sectional study
- Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome
- Is FGF23 effective on insulin resistance in individuals with metabolic syndrome?
- Review Article
- Circulating low density lipoprotein (LDL)
- Case Report
- Congenital complete heart block in pregnancy
